

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

05 JUL -5 PM 5: 12

LOBBYING REGISTRATION

Lobbying Disclosure Act of 1995 (Section 4)

1. Effective Date of Registration 06/20/0
 2. House Identification Number 36969 Senate Identification Number 286096

REGISTRANT

3. Registrant name Organization The McManus Group
 Address 660 Pennsylvania Ave. SE Suite 300
 City Washington State DC Zip 20003 U
 4. Principal place of business (if different than line 3)
 City _____ State _____ Zip _____
 5. Telephone number and contact name Prefix Full Name
(202) 548-2317 Contact Mr. John McManus E-mail jmcmanus@mcmanusgrp.c
 6. General description of registrant's business or activities
Health care consulting and lobbying

CLIENT *A Lobbying firm is required to file a separate registration for each client. Organizations employing in-house lobbyists should check the labeled "Self" and proceed to line 10.* Self

7. Client name Pfizer, Inc.
 Address 325 7th St. NW, Suite 1200
 City Washington State DC Zip 20004 Country U
 8. Principal place of business (if different than line 7)
 City New York State NY Zip 10017 Country U
 9. General description of client's business or activities
Pharmaceutical Manufacturer

LOBBYISTS

Go to page 3 to add mo

10. Name of each individual who has acted or is expected to act as a lobbyist for the client identified on line 7. If any person section has served as a "covered executive branch official" or "covered legislative branch official" within two years of a lobbyist for the client, state the executive and/or legislative position(s) in which the person served.

First	Name		Covered Official Position (if applicable)
	Last	Suffix	
John	McManus		Staff Director, Ways and Means Health Subcommittee

Registrant Name The McManus Group Client Name Pfizer, Inc.

LOBBYING ISSUES Find the code to select below. *Go to page 3 to add more lobbyi*
11. General lobbying issue areas. Select all applicable codes listed in instructions and on the reverse side of Form LD-1, p

PHA MMM _____

12. Specific lobbying issues (current and anticipated)

Implementation of Part D drug benefit. Ensuring patients have adequate access to Pfizer products.

AFFILIATED ORGANIZATIONS *Go to page 3 to add more orgs*

13. Is there an entity other than the client that contributes more than \$10,000 to the lobbying activities of the registrant in a semiannual period and in whole or in major part plans supervises or controls the registrant's lobbying activities?

No ⇨ Go to line 14. Yes ⇨ Complete the rest of this section for each entity matchin criteria above, then proceed to line 14.

Name	Address	Principal place of Busine (city and state or count

FOREIGN ENTITIES *Go to page 3 to add more fore*

14. Is there any foreign entity that:

- a) holds at least 20% equitable ownership in the client or any organization identified on line 13: **OR**
- b) directly or indirectly, in whole or in major part, plans, supervises, controls, directs, finances or subsidizes a the client or any organization identified on line 13; **OR**
- c) is an affiliate of the client or any organization identified on line 13 and has a direct interest in the outcome lobbying activity?

No ⇨ Sign and date the registration. Yes ⇨ Complete the rest of this section for each ent matching the criteria above, then sign and da registration.

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities
	Street Address City	State/Province	Country		

Form Co

Printed Name and Title John McManus, President, The McManus Group 

7/5/05